

Q-linea receives contract for second US ASTar instrument

Q-linea AB (publ) (OMX: QLINEA) today announces the signing of the second US commercial contract for ASTar® instrumentation.

Installation and training will take place by the end of Q1 2025 in a multi-hospital system. Stuart Gander, President & CEO of Q-linea, stated, “We are excited by our ongoing commercial progress and look forward to demonstrating improved clinical outcomes for patients with bacteremia within this healthcare system.”

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Q-linea receives contract for second US ASTar instrument](#)